Opko Health Inc Stock News

OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.

OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall fourth-quarter results reflect soft performances.

While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics com

OPKO Health, Inc. (OPK) Q4 2023 Earnings Call Transcript

OPKO Health (OPK) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.11 per share a year ago.

MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2023 after the close of the U.S.

Active traders use many fundamental or technical signals to set up their trades. Stocks exhibiting heavy insider buying can be one of these signals.

The number of notable insider purchases in mid-January may have been somewhat small, but a couple from the Oracle of Omaha made headlines.

OPKO Health's (OPK) potential in Rayaldee raises optimism about the stock.

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall third-quarter results reflect soft performances.

Although the revenue and EPS for OPKO Health (OPK) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall

MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2023 after the close of the U

MIAMI, Oct. 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) will present late-breaking clinical data on RAYALDEE® extended-release calcifediol (ERC) at the American Society of Nephrology

OPKO Health's (OPK) latest awarded funding is likely to enable the development of novel multispecific antibodies against viral infectious disease threats.